In a move that health professionals say will improve diagnosis and treatment for millions of women worldwide, polycystic ovary syndrome (PCOS) has been officially renamed to poly-endocrine metabolic ovarian syndrome, or PMOS. The change reflects growing scientific understanding that the condition is far more than an ovarian issue — it involves widespread endocrine and metabolic dysfunction.
Experts argue the old name was misleading, since not all women with the syndrome actually have ovarian cysts, and the condition’s most serious effects involve insulin resistance, hormonal imbalance, and metabolic risk factors. The renaming is expected to lead to fewer misdiagnoses and more targeted treatment approaches.
